These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35076845)

  • 1. Blocking TNF signaling may save lives in COVID-19 infection.
    Ablamunits V; Lepsy C
    Mol Biol Rep; 2022 Mar; 49(3):2303-2309. PubMed ID: 35076845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
    Dzobo K; Chiririwa H; Dandara C; Dzobo W
    OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
    Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
    Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review.
    Peddapalli A; Gehani M; Kalle AM; Peddapalli SR; Peter AE; Sharad S
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33673529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling.
    Gajjela BK; Zhou MM
    Drug Discov Today; 2022 Feb; 27(2):390-400. PubMed ID: 34743903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm.
    Rehan M; Ahmed F; Howladar SM; Refai MY; Baeissa HM; Zughaibi TA; Kedwa KM; Jamal MS
    Front Immunol; 2021; 12():648250. PubMed ID: 34248936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
    Front Immunol; 2021; 12():749291. PubMed ID: 34867978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
    Chen XY; Yan BX; Man XY
    Ther Adv Respir Dis; 2020; 14():1753466620926800. PubMed ID: 32436460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
    Gangemi S; Tonacci A
    Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in silico analysis identifies drugs potentially modulating the cytokine storm triggered by SARS-CoV-2 infection.
    Sanchez-Burgos L; Gómez-López G; Al-Shahrour F; Fernandez-Capetillo O
    Sci Rep; 2022 Jan; 12(1):1626. PubMed ID: 35102208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients.
    Hariharan A; Hakeem AR; Radhakrishnan S; Reddy MS; Rela M
    Inflammopharmacology; 2021 Feb; 29(1):91-100. PubMed ID: 33159646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is IL-6 a key cytokine target for therapy in COVID-19?
    Jones SA; Hunter CA
    Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
    Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
    Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal M2 macrophage-derived extracellular vesicles as natural multitarget nanotherapeutics to attenuate cytokine storms after severe infections.
    Wang Y; Liu S; Li L; Li L; Zhou X; Wan M; Lou P; Zhao M; Lv K; Yuan Y; Chen Y; Lu Y; Cheng J; Liu J
    J Control Release; 2022 Sep; 349():118-132. PubMed ID: 35792186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
    Ahmed F
    Front Immunol; 2020; 11():590459. PubMed ID: 33362771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6
    Ettich J; Werner J; Weitz HT; Mueller E; Schwarzer R; Lang PA; Scheller J; Moll JM
    J Virol; 2022 Feb; 96(4):e0162221. PubMed ID: 34935434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2.
    Cheon SY; Koo BN
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
    Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
    Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.